Corvus Pharmaceuticals logo

Corvus Pharmaceuticals

CRVS | NASDAQ
Chart Builder DCF Calculator
$10.60
-$0.04 (-0.38%)
At close: Nov 16, 2026, 4:00 PM ET
$10.81
+$0.21 (+1.98%)
After-hours: Nov 16, 2026, 7:50 PM ET
-0.38%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
37
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #612/1021 (Top 60%)

Key Statistics

Market Data

Market Cap $980.37M
1D Range
10.43 11.05
52W Range
6.50 25.52

Valuation (TTM)

PE -14.32
PB 4.71
EV/EBITDA -12.40

Valuation (NTM)

Forward PE N/A
Forward PEG -0.06
Price Target $27.00
Loading financial charts...

Profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupa...

Sector Healthcare
Industry Biotechnology
Employees 37
IPO Date Mar 23, 2016
Fiscal Year January - December

Latest News

Corvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real Product

6 days ago · seekingalpha.com

Corvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real Product
Corvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027

7 days ago · seekingalpha.com

Corvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

3 months ago · globenewswire.com

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals Q2 Earnings Call Highlights

3 months ago · marketbeat.com

Corvus Pharmaceuticals Q2 Earnings Call Highlights
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?

5 months ago · fool.com

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early

6 months ago · seekingalpha.com

Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early

6 months ago · fool.com

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript

6 months ago · seekingalpha.com

Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

7 months ago · globenewswire.com

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$27.00
Upside
+154.72%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.